ABIONYX Pharma's Half-Yearly Review of Liquidity Contract

ABIONYX Pharma has published its half-year report for the liquidity contract with TP ICAP (Europe). As of December 31, 2025, the liquidity account held 63,024 shares. The cash balance amounted to €250,951.67. During the second half of 2025, 437,203 shares were purchased for €1,389,323.53, and 536,477 shares were sold for €1,560,333.66, through 369 and 502 transactions, respectively.

As of June 30, 2025, the liquidity account contained 162,298 shares and €86,279.52 in cash. Initially, 131,000 shares and €40,801.20 in cash were made available when the contract was established. This balance sheet demonstrates sustained trading activity and a significant increase in buy and sell transactions, as well as an improvement in the cash balance compared to the previous period.